World's Best Scientists 2026 revealed!
Terje R. Pedersen

Terje R. Pedersen

D-Index & Metrics

Medicine

D-Index
99
Citations
104115
World Ranking
8381
National Ranking
32

Terje R. Pedersen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Terje R. Pedersen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 331 publications — 23rd percentile

23% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Terje R. Pedersen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Terje R. Pedersen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Terje R. Pedersen is affiliated with Oslo University Hospital in Norway. Their research primarily spans the fields of Medicine and Economics, Econometrics and Finance, with a particular focus on Surgery, Economics and Econometrics, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Immunology.

The scientist's work is concentrated on topics related to Lipoproteins and Cardiovascular Health, Health Systems and Economic Evaluations, Diabetes and Cardiovascular Risks linked to Lipoproteins, Atherosclerosis and Cardiovascular Diseases, Pharmaceutical Economics and Policy, Acute Myocardial Infarction Research, and Cardiovascular Health and Risk Factors.

Frequent coauthors contributing to their research include Marc S. Sabatine, Anthony Keech, Robert P. Giugliano, Sabina A. Murphy, and Huei Wang.

Terje R. Pedersen has published articles in several notable venues, with repeated publications in JAMA Cardiology and Circulation, and additional contributions to the Russian Journal of Cardiology, The Lancet, and Stroke.

Selected recent papers authored or coauthored by Terje R. Pedersen include:

  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, 2020, Russian Journal of Cardiology
  • Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials, 2022, The Lancet
  • Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis, 2020, Stroke
  • An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial, 2020, JAMA Cardiology
  • LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial, 2020, European Journal of Preventive Cardiology

Best Publications

  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    A.G. Olsson;J McMurray;G Thorgeirsson;C Spaulding

  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

    François Mach;Colin Baigent;Alberico L Catapano;Konstantinos C Koskinas

  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    Marc S. Sabatine;Robert P. Giugliano;Anthony C. Keech;Narimon Honarpour

  • European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

    J Perk;G De Backer;H Gohlke;I Graham

  • 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

    A Halliday;C Baigent;F Mach;B Mihaylova;B Mihaylova

  • 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

    Alberico L. Catapano;Ian Graham;Guy De Backer;Olov Wiklund

  • Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

    Naveed Sattar;David Preiss;Heather M Murray;Paul Welsh

  • The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

    Colin Baigent;Martin J Landray;Christina Reith;Jonathan Emberson

  • Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

    Pyŏrälä K;Pedersen Tr;Kjekshus J;Faergeman O

  • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

    Terje R. Pedersen;Ole Faergeman;John J. P. Kastelein;Anders G. Olsson

  • Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

    Anne B. Rossebø;Terje R. Pedersen;Kurt Boman;Philippe Brudi

  • Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial

    James A de Lemos;Michael A. Blazing;Stephen D. Wiviott;Eldrin F. Lewis

  • Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis

    David Preiss;Sreenivasa Rao Kondapally Seshasai;Paul Welsh;Sabina A. Murphy

  • Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials

    J Fulcher;R O'Connell;M Voysey

  • EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

    R. Agca;S. C. Heslinga;S. Rollefstad;M. Heslinga

  • 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

    Alberico L. Catapano;Ian Graham;Guy De Backer;Olov Wiklund

  • Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

    Hallvard Holdaas;Bengt Fellstrom;Alan G Jardine;Ingar Holme

  • Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis

    S. Matthijs Boekholdt;Benoit J. Arsenault;Samia Mora;Terje R. Pedersen

  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    Terje R Pedersen

  • Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

    David Preiss;Sreenivasa Rao Kondapally;Paul Welsh;Sabina A. Murphy

Frequent Co-Authors

Ingar Holme
Ingar Holme Norwegian School of Sport Sciences
Anders G. Olsson
Anders G. Olsson Karolinska Institute
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Anthony C. Keech
Anthony C. Keech University of Sydney
Robert P. Giugliano
Robert P. Giugliano Brigham and Women's Hospital
Peter S. Sever
Peter S. Sever Imperial College London
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
John Kjekshus
John Kjekshus University of Oslo
Sabina A. Murphy
Sabina A. Murphy Brigham and Women's Hospital
Kristian Wachtell
Kristian Wachtell Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine, there are several online degrees and career pathways that offer flexibility and specialized skills for a rewarding healthcare career. Many students pursue foundational programs, such as an online degree in nutrition, which opens doors to roles in wellness, dietetics, and preventive care.

For working adults interested in advancing to healthcare management or administration, finding whats the best online mha program for working adults can make a big difference in career growth while balancing work and study.

Nursing professionals looking to enhance their credentials may benefit from rn to bsn programs that do not require traditional clinicals, making it easier for active RNs to complete their degrees online.

For those seeking the highest clinical roles in nursing, some of the online dnp programs offer fast and flexible pathways to a Doctor of Nursing Practice degree, preparing you for leadership, advanced practice, or academic roles.

Best Scientists Citing Terje R. Pedersen

Trending Scientists

Recently Published Articles